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Abstract
Introduction Input from patients and healthcare professionals to regulatory assessments is essential for benefit–risk manage-
ment of medicines. How to best obtain input in different risk scenarios is uncertain.
Objectives The objective of this study was to investigate whether the International Risk Governance Council (IRGC) Frame-
work is applicable to pharmacovigilance and can guide selecting engagement mechanisms for optimising stakeholder input.
Methods For proof-of-concept, classify ‘iconic’ cases of pharmacovigilance engagement at the European Medicines Agency 
(EMA) by IRGC risk scenario types and compare the engagement that happened with the engagement discourse recom-
mended by the IRGC Framework for different risk scenarios. If the concept is proven, derive proposals for strengthening 
engagement.
Results Six iconic cases were classified by risk scenario type at the respective time points when deciding on engagement: 
venous thromboembolism with combined hormonal contraceptives (complex risk); lipodystrophy with highly active antiret-
roviral therapy medicines, carcinogenicity with contaminated nelfinavir products (uncertain risks); teratogenicity with tha-
lidomide, progressive multifocal leukoencephalopathy with natalizumab, teratogenicity and developmental disorders with 
valproate (ambiguous risks). The comparison of the engagement events with IRGC recommendations showed correspondence 
between the scope/outcomes of the events and the features of the recommended discourse.
Conclusions The IRGC Framework appears applicable to pharmacovigilance. Proposals derived from the IRGC recom-
mendations may be valuable for guiding regulators when selecting mechanisms for engagement with patients and healthcare 
professionals in given risk scenarios. The proposed decision guide aims at ensuring systematic and consistent engagement 
across regulatory assessments and providing for the most purposeful discourse, to effectively obtain real-world input for 
regulatory risk assessment, evaluation of risk minimisation measures and decision making.
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1 Introduction
Collaboration of all stakeholders involved in developing 
or using medicines, and input specifically from patients 
and healthcare professionals, are considered essential for 
effective pharmacovigilance and benefit–risk management 
of medicines [1–3]. Such input may give insights into the 
use of medicines, the meaning of risks in healthcare and 
patient life, the occurrence of adverse reactions and its cir-
cumstances, as well as the impact of risks, risk commu-
nication and measures for risk management, all with the 
view to understand and improve patient safety. Therefore, 
regulatory bodies nowadays solicit more often, and more 
comprehensively, real-world input from patient and health-
care professional representatives to support risk assessments 
and decision making on granting and maintaining marketing 
authorisations of medicinal products, and to inform related 
regulatory policies. Product-related decisions in the post-
authorisation phase relate mostly to safe use advice, restric-
tions of use and other specific risk minimisation measures; 
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Key Points 
Points to consider for engagement of regulators, patients 
and healthcare professionals are under development 
at the European Medicines Agency (EMA) in order to 
ensure systematic, consistent and effective engagement 
for real-world input to risk assessments, evaluation of 
risk minimisation measures and decision making.
The analysis of six cases of major safety concerns for 
which different engagement mechanisms were used by 
EMA for the first time shows that the framework of the 
International Risk Governance Council (IRGC) appears 
applicable to pharmacovigilance activities.
A decision guide that brings together the IRGC recom-
mendations and the regulatory risk assessment process, 
to support selecting discourse types and engagement 
mechanisms in given risk scenarios, is proposed for 
piloting at EMA and refinement as a tool for regulators.
to lead to positive changes in understandings, attitudes, 
behaviours and policies as the main direct outcomes, and 
ultimately to lead to positive health outcomes. Conceptually, 
engagement is seen as having multiple dimensions, both at 
process and outcome level [4] (see Table 1).
1.2  Mechanisms for Regulatory Engagement 
at the European Medicines Agency
In the European Union (EU), the European Medicines 
Agency (EMA) has, since its establishment in 1995, increas-
ingly responded to patients’ and healthcare professionals’ 
calls for involvement, taken initiatives to drive mutual 
engagement further, and thus over time established dif-
ferent engagement mechanisms. New legislation in 2012 
replaced the Pharmacovigilance Working Party of EMA’s 
Committee for Medicinal Products for Human Use (CHMP) 
with the Pharmacovigilance Risk Assessment Committee 
(PRAC), which has members coming not only from the 
competent authorities of each EU Member State but also 
from the patient and healthcare professional communities. 
In addition, PRAC has made use of all available mecha-
nisms for engagement events to support their assessments 
(see Table 2). Between 2015 and 2019, PRAC initiated 130 
engagement events for 71 medicinal products. The majority 
of these events were written consultations, mostly for the 
review of safety communications, while 22 events involved 
deeper forms of engagement with in-person, face-to-face 
interactions. PRAC is also interested in the involvement of 
patients and healthcare professionals in planning and evalu-
ating risk minimisation measures to support the safe use of 
medicines in healthcare. This interest stems from PRAC’s 
experience that current evaluations of these measures, 
legally imposed and provided by marketing authorisation 
holders as post-authorisation safety studies, do not always 
demonstrate effectiveness in terms of achieving the defined 
risk minimisation objectives or that the methods evaluating 
effectiveness are not always robust. Current evaluations may 
also not reveal why measures are not effective.
Questions about how to best obtain stakeholder input 
for different safety concerns and for different kinds of input 
needed during risk assessments have been raised by PRAC 
in the context of its ‘Strategy for Measuring the Impact of 
Pharmacovigilance Activities’ [6]. Especially challenging 
Table 1  Dimensions of stakeholder engagement for pharmacovigilance purposes [4]
Dimension Description
Breadth Quantity and diversity of stakeholders
Depth Extent of knowledge shared (in order of increasing depth: information, consultation and participation [5])
Texture Interactive dynamics of what the engagement feels like, what it means to people, and how this shapes 
motivations to engage and change behaviours based on values, emotions, (mis)trust and rationales
other options include further investigations, keeping a safety 
concern under close monitoring, precautionary measures, 
suspension of marketing or withdrawal of the marketing 
authorisation. A risk assessment may also conclude that no 
action is necessary.
1.1  Concept of Pharmacovigilance Engagement
Stakeholder engagement for pharmacovigilance purposes 
has recently been conceptualised as an ongoing process of 
knowledge exchange among stakeholders. The term ‘engage-
ment’ implies the crucially important mutuality of this pro-
cess. Pharmacovigilance stakeholders include patients and 
their carers, healthcare professionals, regulatory bodies, 
other health and healthcare organisations, marketing authori-
sation holders and industry in general, academia, and the 
wider public. The process is enacted through engagement 
events with the steps of preparing, conducting and evaluat-
ing such events. Knowledge exchange refers to sharing per-
spectives, norms, values and meanings as well as scientific 
and real-world knowledge. Adoption of knowledge is meant 
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are safety concerns that carry uncertainty or controversy 
regarding the evidence on the risk and the impact of pos-
sible regulatory actions. Such questions are also discussed 
in the US [7], where a series of guidance from the US Food 
and Drug Administration on enhanced incorporation of the 
‘patient’s voice’ in medicines development and regulatory 
decisions are currently being drawn up [8]. While the US 
FDA holds a public hearing for each advisory committee 
meeting [9], PRAC has so far convened only two public 
hearings. The option of a public hearing was added for cer-
tain regulatory procedures by EU legislation that came into 
force in 2012. High-level criteria are applied by PRAC when 
deciding to call for a hearing or choose another engagement 
mechanism instead. These criteria are feasibility to hold a 
public hearing in light of the urgency of the matter; nature 
and extent of the safety concern; therapeutic effect of the 
medicine and availability of therapeutic alternatives; poten-
tial impact of regulatory actions on therapeutic practice and 
availability of treatments; and level of public interest [10]. 
The criterion ‘nature and extent of the safety concern’ has 
so far not been further detailed beyond the seriousness and 
frequency of the identified or potential adverse reaction; 
this constitutes an area of uncertainty regarding deciding 
on how to arrange for systematic, consistent and effective 
engagement.
1.3  International Risk Governance Framework
In general, safety concerns arise from nature as well as 
technologies, not only in the area of medicine but linked, 
for example, to energy supply, food production, waste man-
agement, environmental and climate change or data secu-
rity. Many civil society movements and organisations have 
started or contributed to the debates, and platforms for their 
interaction with policymakers have been created. It is hence 
of interest to see if experiences with stakeholder engage-
ment in other risk areas may provide learnings for phar-
macovigilance. The International Risk Governance Council 
(IRGC) has established a practical engagement framework 
that builds on the experience from various risk areas. It inte-
grates characteristics of typical risk scenarios with evidence-
based recommendations for risk management strategies 
and discourse within engagement of affected populations, 
experts and other stakeholders [12, 13] (see Table 3). This 
framework has not yet been applied for pharmacovigilance 
purposes; however, its features fit well with the objectives 
and current challenges of pharmacovigilance. Namely, the 
framework supports a multidisciplinary and multistake-
holder approach to risk, aiming to provide and structure 
scientific evidence within the societal context for risk man-
agement and social benefit. It further aims to guide coping 
with risks in situations of high complexity, uncertainty or 
ambiguity, based on principles of transparency, strategic 
focus, efficiency, accountability, sustainability, equity, com-
pliance with the law, and acceptability from the viewpoints 
of ethics, the public and policymaking [12].
2  Objectives
As there is uncertainty about which engagement mechanism 
may be best in given typical scenarios of safety concerns 
with medicines in terms of the nature and extent of the con-
cern, this study investigated whether the IRGC Framework 
[12, 13] is applicable to regulatory pharmacovigilance and 
can possibly guide regulators when selecting mechanisms of 
stakeholder engagement during risk assessment procedures.
Overall, this aims at optimising engagement by ensuring 
that it is systematic and consistent across regulatory proce-
dures and obtains, most effectively, real-world input from 
patients and healthcare professionals for regulatory risk 
assessment, evaluation of risk minimisation measures and 
decision making in different risk scenarios. The results of 
this study are meant to inform ongoing work of the PRAC 
Interest Group on Measuring the Impact of Pharmacovigi-
lance Activities, in particular the development of points to 
consider supporting PRAC in enhancing their engagement 
with patients and healthcare professionals.
Table 2  Mechanisms for stakeholder engagement events available to the Pharmacovigilance Risk Assessment Committee at the European Medi-
cines Agency[11]
EMA European Medicines Agency, EU European Union
Stakeholder mechanism
Written consultations (public and open to all citizens and organisations as announced on the EMA website, e.g. public consultations on guide-
lines and other policy documents, and/or announced to organisations of the EU stakeholder network, e.g. targeted reviews of planned safety 
communication documents)
Dedicated meetings (non-public meetings with stakeholder representatives, in particular patients and healthcare professionals, e.g. so-called ad 
hoc meetings and research oversight meetings)
Participation of additional scientific/clinical experts and/or patient representatives in a meeting of the Scientific Advisory Groups established for 
various therapeutic areas (non-public meetings)
Public hearings (open to all citizens and organisations as announced on the EMA website and provided to the public as life-broadcast)
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3  Methods
The applicability of the IRGC Framework to pharmacovigi-
lance was investigated as a proof-of-concept study by apply-
ing the framework to cases of safety concerns with medicinal 
products for which different mechanisms for engagement 
with patients and healthcare professionals were used at EMA 
for the first time during a risk assessment procedure (see 
Table 4). In this article, these cases are referred to as ‘iconic’ 
in the meaning of ‘distinctive’, ‘symbolic’, ‘impressive’ and 
‘widely recognised’ [14–16], as these cases are well-known 
and frequently referred to in the pharmacovigilance as well 
as patient advocacy communities. Cases of the first-time use 
of written consultations on draft wording of product infor-
mation, medicines safety advisories on the EMA website 
or direct healthcare professional communications (DHPCs) 
were excluded in order to focus on deeper (and still rarer) 
engagement with face-to-face interaction, including with 
those who have been harmed by medicines.
The applicability analysis comprised for each iconic case: 
(1) classifying the safety concern as it was understood at the 
time point of deciding on engagement according to the IRGC 
risk scenario typology (see Table 3); and (2) characterising 
the engagement event that happened in terms of mechanism 
(see Table 2), scope and the dimensions of breadth, depth 
and texture (see Table 1), and comparing it with the engage-
ment discourse recommended by the IRGC Framework for 
the different risk scenarios (see Table 3).
The analysis used regulatory documentation published 
by EMA and published case studies as referenced, as well 
as some internal EMA working documents to cross-check 
details of the arrangements for the engagement events.
The analytical approach was consulted with the PRAC 
Interest Group on Measuring the Impact of Pharmacovigi-
lance Activities, which includes patient and healthcare 
professional representatives. The case studies used for the 
analysis also involved patient views, interviews and surveys.
The potential for researcher bias in data interpretation 
was minimised by a structured approach to data analysis, 
inclusion of results from published case studies and a review 
of the analysis from the first author by the second author.
As the concept was proven, proposals were derived from 
the IRGC Framework for guiding regulators when selecting 
engagement mechanisms for different risk scenarios. Had 
the proof-of-concept analysis led to a negative result, fur-
ther investigations on the specifics of risks with medicines 
and different needs for risk governance would have been 
warranted.
4  Results of the Proof‑of‑Concept Study
The risk scenario classification step of analysing the iconic 
cases showed that none of the risks for which the various 
engagement mechanisms were used for the first time at EMA 
could be classified as a simple risk. One case, i.e. combined 
hormonal contraceptives (CHCs), was classified as a com-
plex risk; two cases, i.e. medicines used for highly active 
antiretroviral therapy (HAART) and nelfinavir-containing 
products, were classified as uncertain risks at the time of ini-
tiating engagement; and three cases, i.e. thalidomide, natali-
zumab and valproate, were classified as ambiguous risks.
The next step of the analysis, i.e. comparing the engage-
ment mechanisms used in the iconic cases with the engage-
ment discourse types recommended by the IRGC Framework 
for the various risk scenarios, showed the following: EU 
regulators, while not aware of the IRGC Framework, decided 
on engagement that was consistent with the IRGC recom-
mendations. For the complex risk of CHCs, the scope of the 
dedicated meeting and its outcome to present risk estimates 
Table 4  Iconic cases of pharmacovigilance engagement at the European Medicines Agency, in chronological order
EMA European Medicines Agency
Iconic case of pharmacovigilance engagement
Risk of lipodystrophy with medicines used for highly active antiretroviral therapy: First-time engagement of patient and healthcare profes-
sional representatives in a multistakeholder oversight committee for research requested by EMA for an adverse reaction suspected and notified 
by patients themselves (1999)
Risk of potential carcinogenicity with contaminated nelfinavir-containing products: First-time engagement of EMA where a patient 
representative was contacted by EMA immediately after a marketing authorisation holder’s notification of a quality defect and before the risk 
assessment could be started. [Note: The risk assessment demonstrated that the exposure of patients had been below the toxic threshold] (2007)
Risk of teratogenicity with thalidomide: First-time engagement of EMA where victim and patient representatives were brought together at a 
dedicated meeting (2007)
Risk of progressive multifocal leukoencephalopathy with natalizumab: First-time invitation of patient representatives in a Scientific Advi-
sory Group meeting at EMA regarding the risk of an authorised medicine (2008)
Risk of venous thromboembolism with combined hormonal contraceptives: First-time dedicated meeting with patient and healthcare profes-
sional representatives for EMA’s Pharmacovigilance Risk Assessment Committee established in July 2012 under then new legislation (2013)
Risk of teratogenicity with valproate: First-time public hearing at EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) (2017)
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in the product information for patients and healthcare pro-
fessionals differently can be seen as corresponding with the 
purpose of an epistemological discourse to resolve cognitive 
conflicts between stakeholders regarding risk characteristics, 
estimates and risk minimisation action. For the, at the time, 
uncertain risk of HAART products, the engagement scope 
of multistakeholder research oversight corresponds with the 
purpose of a reflective discourse to collectively assess risk. 
For nelfinavir-containing products, the engagement scope 
included motivating patients to seek appropriate treatment 
management. This can be interpreted as an engagement dis-
course with reflection on the trade-offs between the needs 
for further risk assessment and safeguarding patient health 
during investigations and precautionary product suspen-
sion. For the ambiguous features of the risks of thalidomide, 
natalizumab and valproate, the engagement events can all be 
analysed as corresponding with a participative discourse. 
In all these three cases, considerations that patients should 
not be deprived from necessary and beneficial treatments, 
provided that risk minimisation measures can be agreed that 
are effective and satisfactory to all stakeholders affected dif-
ferently, were at the core of engagement (see Table 5).
The results of the analysis can be taken as proof that the 
IRGC Framework appears applicable to pharmacovigilance 
and that the IRGC recommendations may be valuable for 
guiding regulatory pharmacovigilance engagement.
5  Discussion
This proof-of-concept study demonstrated that the IRGC 
Framework, which is  well-established for stakeholder 
engagement in various risk areas of nature and technology, 
also appears applicable to pharmacovigilance, as EU regu-
lators, albeit not consciously, engaged with stakeholders in 
iconic cases of safety concerns with medicines over the past 
two decades in ways that correspond remarkably with the 
nature of engagement that would have emerged if the IRGC 
Framework had been applied.
We can only speculate why the IRGC Framework has not 
been applied for pharmacovigilance purposes yet. Maybe 
the comprehensive regulation of medicines has long been 
viewed as a sufficient framework for risk governance. At 
the origin of this regulation more than 50 years ago, patients 
have likely been seen, only in a traditional perspective, as 
vulnerable and to be cared for. However, their active role 
in regulatory activities has been steadily increasing, at the 
latest since the patient advocacy for anti-human immunode-
ficiency virus (HIV) treatments in the 1980s [24, 25]. This 
study confirms that EMA, almost immediately after becom-
ing operational in 1995, embraced, welcomed and encour-
aged the active role of patient and healthcare professional 
representatives in regulatory pharmacovigilance activities.
The iconic cases that were analysed in this study occurred 
between 1999 and 2017, and their crucial importance for 
gradually building up more participation and trust of stake-
holders in the EU regulatory pharmacovigilance system 
can, from an EMA perspective, not be underestimated. The 
trust in EMA’s high safety standards was also reiterated 
recently by stakeholders at a public EMA meeting on vac-
cines against COVID-19, the disease caused by the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
[36]. The importance of the iconic cases justifies their analy-
sis to learn for the future.
Uncertainty has been expressed by PRAC about opti-
mal stakeholder engagement, together with their intent to 
enhance engagement in systematic and consistent manner 
across all regulatory risk assessments as part of the PRAC 
Impact Strategy [6]. Hence, considering the recommenda-
tions of the IRGC Framework may be valuable for guiding 
pharmacovigilance engagement when selecting engagement 
mechanisms for effectively obtaining input from patients and 
healthcare professionals for regulatory risk assessments and 
decision making. For developing this further on the basis of 
established approaches to regulatory risk assessment, the 
following is raised for discussion here.
5.1  Classification of Safety Concerns with Medicines 
According to the International Risk Governance 
Council (IRGC) Risk Scenario Typology
Although real risks often present as a combination of risk 
types [12], most of the safety concerns of the iconic cases 
could be clearly classified according to the IRGC risk sce-
nario typology. One case was difficult to classify. For natali-
zumab, the risk classification as an uncertain or ambigu-
ous risk was considered in favour of ambiguous risk; first, 
because the IRGC Framework views uncertainty as intrinsic 
to human knowledge and thus to any risk assessment [13]. 
In fact, once medicines have been authorised on the basis 
of clinical trial data, safety concerns identified in the post-
authorisation phase mainly relate to potential adverse reac-
tions that are uncommon rare, occur in patients with specific 
conditions, or have a delayed onset. Dealing with uncer-
tainty of evidence is therefore intrinsic to pharmacovigilance 
and risk assessment, from both the clinical diagnosis and 
the statistical data analysis points of view, and with regard 
to causality assessment. The second rationale for classifying 
the natalizumab case as an ambiguous risk was that patient 
views were crucial for the regulators’ decision making, i.e. to 
either conclude with a negative benefit–risk assessment, or 
positively with risk acceptance given the value of the treat-
ment benefit for patients. The existence of divergent perspec-
tives was postulated for the risk classification, due to known 
patient advocacy for maintaining this treatment option on 
the one hand and regulators’ obligations for patient safety 
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on the other, although there was never a declared conflict 
between patients and regulators. Actually, in the pre- and 
post-authorisation phases, both parties had always converged 
on the need for considering the risk-benefit balance carefully 
and for potentially identifying suitable patient groups and 
risk minimisation measures [29–31].
5.2  Changes in Risk Scenario Type During 
Regulatory Risk Assessment
For the analysis of the iconic cases, the risk scenario type 
was determined as the safety concern was understood before 
deciding on engagement and finalising the risk assessment. 
This mimicked the situation when regulators agree time-
tables for risk assessment procedures, including interac-
tions with stakeholders. However, during risk assessment, 
the knowledge on the safety concern often changes, and so 
may the risk scenario: uncertainty usually decreases, but 
can sometimes also increase when limitations in evidence 
are identified; complexity often persists; and ambiguity may 
become apparent only during the assessment or engagement 
when different stakeholder perspectives are presented. In 
the case of nelfinavir for example, precautionary action had 
to be taken urgently, while investigations of the risk, per-
formed as quickly as possible, moved it from an uncertain 
risk to a complex and even simple risk (eventually, it could 
be concluded that patient exposure had been below the toxic 
threshold) [20, 26].
5.3  Compatibility of IRGC Discourse 
Recommendations with Medicines Regulation
Safety concerns with medicines are assessed by PRAC under 
various regulatory procedures legally prescribed by the 
source and type of new safety information, the urgency of 
the safety concern, the kind of medicinal products involved, 
the authorisation status of these product(s), and some-
times by their link with other procedures ongoing for the 
product(s). Therefore, the following points require discus-
sion when applying the IRGC discourse recommendations 
to regulatory procedures for risk assessment:
Availability of Engagement Mechanisms: With the estab-
lishment of PRAC under then new legislation in 2012, the 
PRAC members from the competent authorities in EU 
Member States were provided with two major novelties for 
strengthening stakeholder engagement; namely, (1) exten-
sion of PRAC membership by one additional member and 
one alternate member appointed by the European Commis-
sion from each of the patient and healthcare professional 
communities, and (2) the option for PRAC to call for public 
hearings during specific regulatory procedures, i.e. ‘refer-
rals’ [10, 37]. While PRAC’s choice for a hearing allow-
ing for a participative discourse in the public domain is 
restricted to specific regulatory procedures, EMA has also 
announced dedicated meetings to the public and arranged for 
wide stakeholder interaction when needed, as in the cases 
of thalidomide and natalizumab. Furthermore, EMA holds 
public meetings, albeit not hearings, when major health con-
cerns demand this, just as with the current SARS-CoV-2 
pandemic.
Publicity and Patient Privacy of Engagement: Publicity 
is an important element of patient advocacy for “visibility 
to the world” (François Houÿez, European Organisation for 
Rare Diseases [EURORDIS], personal communication, 3 
March 2020) and may hence be important to patient repre-
sentatives in regulatory activities. However, patients also 
have a right to privacy, and there could be situations where 
individuals prefer a (participative) discourse with regula-
tors that does not happen in the public domain. PRAC has 
experienced that finding patient representatives willing to 
engage can be difficult even for a closed meeting, as hap-
pened, for example, when PRAC wanted to explore why 
risk minimisation measures for preventing pregnancy during 
treatment with isotretinoin had not been fully effective and 
how to improve the measures.
Timing of Engagement: As regulatory procedures are 
subject to legally imposed timetables, stakeholder engage-
ment must be organised in ways that do not delay regula-
tory action necessary for patient safety. For public hearings, 
EU legislation even states explicitly that they may be held 
“where the urgency of the matter permits” [37], which rec-
ognises that the orderly conduct of such hearings requires 
preparation. Notably, many patient and healthcare profes-
sional representatives have shown remarkable commitment 
to respond to the EMA’s calls within tight timeframes. Writ-
ten consultations of urgent communication documents are 
sometimes finalised even within a few hours.
Availability of Stakeholders: Stakeholder engagement 
in regulatory activities is pro bono; currently, only travel 
expenses and daily allowances are provided by EMA to 
patient and healthcare professional representatives. The 
representatives may also have to donate their free time off 
work for travelling and attending EMA meetings. In addi-
tion, consultations and meetings are held in English as the 
EMA working language. These circumstances restrict the 
availability of representatives and may hinder regulators to 
hear from all patient, healthcare professional and society 
segments. In particular, the vast majority of patients are not 
members of a patient organisation that could make them 
aware of and prepare them for opportunities of engagement. 
On the other hand, in some situations even the engagement 
with a very small breadth at engagement process level can 
have a wide breadth at engagement outcome level, as shown 
by the nelfinavir case. In this case, a single patient represent-
ative could achieve a high positive impact in terms of treat-
ment management of many patients, as he was an individual 
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well-recognised and highly trusted in the patient community 
[26]. In particular, where regulatory action needs to be taken 
urgently or within a short time frame, an appropriate breadth 
of engagement might have to be achieved by finding a few 
patients and healthcare professionals who can act in inter-
mediary roles or present a full range of perspectives, because 
interacting with many people might not be feasible due to 
limited stakeholder availability. However, with a general 
view, questions about who are the public, in how far it is a 
coherent entity or how many segments of the public exist, 
and who can represent the public or patient and healthcare 
professional communities have to be investigated for further 
optimising future engagement in regulatory activities [38].
Accountability: EU legislation provides for engagement 
of stakeholders and transparency [37]. A recent policy analy-
sis reported a high degree of transparency of EMA’s risk 
assessments prescribed by the legislation and EMA poli-
cies [39]. While the input from stakeholders to risk assess-
ments is seen by the EU regulatory network as instrumental 
to good decision making, the ultimate legal responsibility 
for risk assessments and the terms of marketing authorisa-
tions remains with the regulators. Their responsibility for 
decisions and implications cannot be shared with any party 
outside the EU regulatory network. While maintaining this 
legal role of the regulators, participatory discourse is meant 
to achieve agreements between regulators and stakehold-
ers and enable regulatory decisions that are responsive and 
accountable to the public.
5.4  Added Value of the IRGC Discourse 
Recommendations for Pharmacovigilance 
Engagement
The IRGC Framework recommends different engage-
ment discourse types for different risk scenario types. The 
term ‘discourse’ describes a formal, orderly and usually 
extended expression of thought on a subject and related 
interchanges in speech or writing [40]. While instrumen-
tal discourse discusses practical aspects of implementing 
risk minimisation action, a discourse of epistemology is 
concerned with maximising what can be known on the risk 
and possible actions. Furthermore, a discourse of reflec-
tive nature aims at agreeing a reasoned way forward despite 
uncertainty, and building resilience for coping with uncer-
tainty and knowledge changes, while a participatory dis-
course is a debate for building tolerance, resolving conflicts 
and establishing common ground between stakeholders, 
and subsequently achieving agreements on risk minimisa-
tion [12, 13] (see Table 3). The framework’s broader vision 
on discourse, rather than on specific formats of engagement 
events, can be seen as adding value for tailoring engage-
ment events to the environment and objectives of regulatory 
pharmacovigilance. This vision encourages deeper thinking 
about which discourse type is most suitable for creating the 
texture of an engagement event that may effectively obtain 
input from stakeholders at any specific stage of risk assess-
ment and enable regulatory decisions that are likely to man-
age the given risk in the given circumstances. This focus on 
texture may help with selecting the appropriate engagement 
mechanism in given risk scenarios and fine-tune the conduct 
of stakeholder interactions. Recent interview research with 
patient organisations in Europe has already identified the 
need for supporting patients engaging in regulatory activities 
with broad awareness campaigns, sessions at patient acad-
emies, and an overall proactive approach of regulatory bod-
ies [41]. The analysis of the iconic cases included the inter-
active dynamics and the dimension of texture overall, and 
highlighted how the respective engagements in these cases 
motivated certain decisions and behaviours of all involved. 
Among more recent PRAC engagement events is the second 
public hearing at EMA in 2018 regarding quinolone antibiot-
ics [42]. The scope of this hearing was mainly for patients to 
detail their adverse experiences after exposure to quinolones. 
According to the IRGC Framework, such an epistemological 
discourse does not necessarily have to happen in the public 
domain. However, other reasons in favour of publicity in the 
case of quinolones could have been important for stakehold-
ers and hence EMA. Therefore, it would be informative to 
review further cases of PRAC engagement for learning and 
systematising future engagement. This could also take into 
account the lessons learnt by EMA from stakeholder interac-
tions in other risk areas that are not led by PRAC, such as 
N-nitrosamine impurities of angiotensin II receptor antago-
nists (medicines against high blood pressure, also known as 
‘sartans’) [43].
5.5  Proposals for Selecting Engagement 
Mechanisms for Regulatory Risk Assessment 
and Decision Making
Given the applicability of the IRGC Framework to phar-
macovigilance, the IRGC discourse recommendations may 
be valuable for deriving a proposed guide for regulators, in 
the EU and possibly elsewhere, as support when selecting 
engagement mechanisms for stakeholder input to regulatory 
risk assessment procedures.
Depth of Engagement: Considering the above discussion, 
it is proposed to select the engagement mechanism that pro-
vides for a more interactive discourse with the potential for 
more depth of engagement whenever there is unclarity over 
the risk scenario type of a given safety concern. It can be 
further proposed to involve stakeholders more than once dur-
ing a risk assessment procedure through various mechanisms 
and with different questions, as the risk might shift the risk 
scenario type during the assessment. In recent years, PRAC 
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has, in some instances, already called upon patients and 
healthcare professional representatives several times during 
the same procedure, with variable levels of depth of engage-
ment for different input needed at the respective assessment 
stage. For example during the valproate assessment, PRAC 
deployed three mechanisms, i.e. a written consultation to 
gather evidence on experiences with previous risk minimi-
sation measures at the beginning of the assessment process 
to reduce uncertainty around the effectiveness of the meas-
ures; the public hearing described above as the appropriate 
engagement mechanism for situations of ambiguity due to 
different stakeholder perspectives; and a subsequent dedi-
cated meeting shortly before regulatory decision making to 
discuss preferences and practicalities of potential future risk 
minimisation measures [33, 34]. The dedicated meeting cor-
responded with an instrumental discourse, which is recom-
mended by the IRGC Framework for simple risk scenarios 
with evidence on causality of the risk and effectiveness 
of existing or possible risk minimisation or precautionary 
measures. For risk management of medicines, an instru-
mental discourse on how to put measures into practice can 
actually be seen as necessary in all four risk scenarios. This 
could happen as formative research before or after a decision 
on regulatory action has been taken. At these time points, the 
discourse can focus on the design, dissemination and further 
aspects of the implementation of measures in healthcare for 
improving patient safety. For the full implementation that 
ensures that the measures reach patients along the clinical 
care pathway, further local instrumental discourse might be 
necessary in healthcare settings.
Breadth of Engagement: Considering the above discus-
sion regarding the compatibility of the IRGC discourse 
recommendations with medicines regulation, the breadth 
of each engagement event should be arranged in ways that 
balance the needs for scope and timeliness of stakeholder 
input with the availability of stakeholders.
Texture of Engagement: Different from written consulta-
tions, face-to-face interactions provide for a higher degree 
of texture. Demonstrating trustworthiness of the regulatory 
body is seen by patient representatives as a major oppor-
tunity offered by a public hearing (François Houÿez, 
EURORDIS, personal communication, 3 March 2020). Rec-
ognising the added value of the IRGC Framework’s vision 
on discourse, as discussed above, may facilitate shaping 
the necessary texture by adapting face-to-face engagement 
events in terms of setting, agenda, understandable language, 
formulation of questions, style of chairing and interactions 
(including needs for publicity or privacy) to the engagement 
mechanism available for the given regulatory procedure.
By matching the IRGC Framework with the regula-
tory risk assessment process and taking into account the 
aspects discussed above, proposals have been derived from 
the IRGC discourse recommendations and consolidated 
as a visual decision guide for regulators when selecting 
engagement mechanisms for different risk scenario types 
(see Fig. 1). This guide also reiterates the objective of the 
engagement discourse in terms of the stakeholder input 
and agreements needed for the regulatory assessment and 
decision making on risk management. Risk minimisation 
measures relate to who can use the product and how the 
product can be used safely, and uses a range of tools, such 
as the product information, pack size, legal status, educa-
tional materials, controlled access programmes, or specific 
sets of combined measures to manage risks of medicines in 
pregnancy [44]. Examples for precautionary measures are 
advice with precautions for use in the product information, 
or marketing suspension while investigations are ongoing 
for the product.
Determining the risk scenario of a given safety concern 
depends not only on the evidence for the risk from a phar-
macological point of view but also on the evidence and 
experience with previous or possible measures for risk man-
agement, the stakeholder perspectives on the risk and the 
measures, and the overall context. All these determinants can 
differ between jurisdictions: risk factors for a certain adverse 
reaction can differ locally; more often, the implementabil-
ity of measures will differ between healthcare systems and 
will require locally optimised measures and implementa-
tion; and stakeholders and their views may also differ locally. 
Therefore, applying the decision guide to the same medicinal 
product risk in different jurisdictions might not necessarily 
result in the same decision on engagement. It is also not the 
intent of the decision guide to harmonise engagement for 
specific medicinal product risk across various jurisdictions; 
the intention instead is to help address local engagement 
needs with a systematic approach.
6  Conclusions
An analysis of six iconic cases of medicine safety concerns 
using different mechanisms for engagement of the EU regu-
latory network with patients and healthcare professionals 
during risk assessment demonstrated that the IRGC Frame-
work appears applicable to pharmacovigilance.
A practical, visual decision guide has therefore been 
derived from the IRGC Framework and tailored for phar-
macovigilance purposes as a proposal for regulators when 
selecting mechanisms for their engagement with patients and 
healthcare professionals. With the decision guide, the risk 
scenario type of a given safety concern with its nature and 
extent can be determined, as well as the matching discourse 
type. This should support ensuring that engagement is sys-
tematic and consistent across safety concerns and regulatory 
procedures, and provides the texture for the most purposeful 
discourse, i.e. to effectively obtain the needed real-world 
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Fig. 1  Decision guide for selecting engagement mechanisms based 
on the discourse type required for different risk scenarios subject to 
regulatory risk assessment. Black frames and arrows indicate items 
relating to the risk scenario and the risk assessment process, while 
blue frames and arrows indicate items relating to the decision on the 
discourse type for stakeholder engagement to support the risk assess-
ment outcome. The respective discourse types recommended for each 
of the four risk scenario types are indicated by the matching colours 
of the boxes depicting the risk scenario and the engagement types
input at the right time point for regulatory risk assessment, 
evaluation of risk minimisation measures and decision mak-
ing. In addition, it should ensure that resources for engage-
ment events are used in an efficient and risk proportionate 
manner for those risk scenarios where engagement is most 
needed.
Adopting specific expertise in effective discourse for 
pharmacovigilance matters and patient safety may facilitate 
strengthening regulatory engagement processes and out-
comes. Expertise in discourse is suggested here as a novel 
competence within pharmacovigilance. The case study on 
valproate (referenced in Table 5) has already resulted in pro-
posals for looking into how engagement can create common 
ground, a sense of shared problem ownership, joint evalua-
tions and agreement on risk management solutions, as well 
as leadership for implementation of risk minimisation or 
precautionary measures in healthcare.
The applicability of the IRGC Framework to pharma-
covigilance has been presented to PRAC. Next, the pro-
posed decision guide is planned to be taken forward with 
considering learnings from more recent engagement events, 
piloting it with current PRAC assessments, and subsequent 
refinement as a truly practical guide. Training for regulators 
involved in PRAC activities on how to apply the guide, along 
with their feedback, will be part of the iterative refinement. 
The decision guide are intended to be integrated into points 
to consider for PRAC, supporting their purposeful use of all 
engagement mechanisms established at EMA. These points 
to consider are under development as part of the PRAC 
Impact Strategy, and will also integrate the existing EMA 
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rules of procedure on public hearings, the pharmacovigi-
lance engagement concept (described in Sect. 1) and the 
Analysing Stakeholder Safety Engagement Tool (ASSET; 
developed through the valproate case study referenced in 
Table 5). The ASSET has been suggested for ensuring that 
stakeholder input is solicited with a view to implementa-
bility of risk minimisation measures in healthcare, because 
some crucial gaps in feedback to regulators from real-world 
healthcare and daily patient life regarding the dissemina-
tion and further implementation of risk minimisation meas-
ures have been identified. Filling these gaps is meant to con-
tribute to improving regulatory risk minimisation measures 
and, ultimately, patient health.
It is important to highlight that the ‘points to consider’ 
on PRAC engagement are being developed with input from 
the representatives of the patient and healthcare professional 
communities participating in PRAC and the PRAC Inter-
est Group on Measuring the Impact of Pharmacovigilance 
Activities. Subsequently, the draft ‘points to consider’ will 
be discussed with the EMA’s Patients' and Consumers' 
Working Party (PCWP) and Healthcare Professionals' Work-
ing Party (HCPWP), to ensure that it will meet stakeholder 
needs, expectations and practicalities.
Although the analysis and its objectives presented in this 
article relate to EMA and its risk assessment committee, 
PRAC, the proposals are derived from a well-established 
international framework and the proposed practical decision 
guide might serve the strengthening of pharmacovigilance 
engagement of regulators globally.
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